prolaio eVO2peak Module vs EchoGo Amyloidosis
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
These tools are adjacent in their comparability, both being FDA-cleared AI solutions within cardiology. Prolaio's eVO2peak Module focuses on estimating peak oxygen consumption from wearable sensor data for general cardiovascular assessment. In contrast, Ultromics' EchoGo Amyloidosis is designed for the early detection of cardiac amyloidosis by analyzing echocardiogram video clips, addressing a specific disease screening need.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
The Prolaio eVO2peak Module is FDA-cleared software designed to estimate peak oxygen consumption (eVO2peak) using real-world patient data, serving as an adjunctive aid in clinical evaluation for cardiovascular research and care. Ultromics' EchoGo Amyloidosis is an FDA-cleared AI-powered screening tool that analyzes echocardiogram video clips to aid in the early detection of cardiac amyloidosis.
The Prolaio eVO2peak Module utilizes demographic data, single-lead ECG, and triaxial accelerometry inputs, processing data from qualified third-party FDA-cleared wearable medical sensors. Ultromics' EchoGo Amyloidosis analyzes echocardiogram video clips to identify suspected cardiac amyloidosis.
The Prolaio eVO2peak Module provides an estimate of peak oxygen consumption as an adjunctive aid in clinical evaluation. Ultromics' EchoGo Amyloidosis provides a diagnostic output of 'suggestive' or 'not suggestive' of cardiac amyloidosis, with reported high diagnostic accuracy (85% sensitivity, 93% specificity).
The Prolaio eVO2peak Module is cloud-based software that processes remote sensor data. Ultromics' EchoGo Amyloidosis is a cloud-based SaaS model designed for seamless integration with existing clinical workflows and IT infrastructure, including PACS, DICOM, and HL7.
For Ultromics' EchoGo Amyloidosis, there are specific codes: Inpatient NTAP Code ICD-10 XXE2X19 ($1,000 per analysis, Medicare-covered) and Outpatient HCPCS Code C9786, Clinical APC Code 574 ($285 per analysis, covered by Medicare and select commercial insurers). Prolaio eVO2peak Module requires contacting the company for pricing.
The Prolaio eVO2peak Module is relevant for Cardiology, Physical Medicine & Rehab, and Sports Medicine. Ultromics' EchoGo Amyloidosis is specifically designed for Cardiology.